Scott R. Ward - 27 Apr 2023 Form 4 Insider Report for Cardiovascular Systems Inc

Role
Chairman and CEO, Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for Scott R. Ward pursuant to Power of Attorney previously filed.
Issuer symbol
N/A
Transactions as of
27 Apr 2023
Net transactions value
-$16,220,440
Form type
4
Filing time
27 Apr 2023, 16:32:08 UTC
Previous filing
14 Feb 2023
Next filing
27 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CSII Common Stock Disposed to Issuer $11,566,200 -578,310 -71% $20.00 232,712 27 Apr 2023 Direct F1
transaction CSII Common Stock Disposed to Issuer $4,654,240 -232,712 -100% $20.00 0 27 Apr 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CSII Restricted Stock Units Disposed to Issuer $0 -34,297 -100% $0.000000* 0 27 Apr 2023 Common Stock 34,297 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Scott R. Ward is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of unvested restricted stock became fully vested immediately prior to the effective time of the merger. Shares of restricted stock were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.
F2 Converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes.
F3 Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.